Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Clinical trial NCT06954480 · RECRUITING

Trial details

NCT number: NCT06954480
Sponsor: Queen Mary University of London
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2025-10-27
Primary completion: 2028-02-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.